RU2761342C2 - Доставка терапевтических агентов в цнс - Google Patents
Доставка терапевтических агентов в цнс Download PDFInfo
- Publication number
- RU2761342C2 RU2761342C2 RU2017125281A RU2017125281A RU2761342C2 RU 2761342 C2 RU2761342 C2 RU 2761342C2 RU 2017125281 A RU2017125281 A RU 2017125281A RU 2017125281 A RU2017125281 A RU 2017125281A RU 2761342 C2 RU2761342 C2 RU 2761342C2
- Authority
- RU
- Russia
- Prior art keywords
- composition
- enzyme
- lysosomal
- storage disease
- activity
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 4
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 19
- 102000004190 Enzymes Human genes 0.000 claims abstract 17
- 108090000790 Enzymes Proteins 0.000 claims abstract 17
- 230000002132 lysosomal effect Effects 0.000 claims abstract 9
- 208000015439 Lysosomal storage disease Diseases 0.000 claims abstract 8
- 230000000694 effects Effects 0.000 claims abstract 7
- 238000007914 intraventricular administration Methods 0.000 claims abstract 6
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 4
- 239000010452 phosphate Substances 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 102100022146 Arylsulfatase A Human genes 0.000 claims 4
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims 4
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims 4
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 4
- 102000005936 beta-Galactosidase Human genes 0.000 claims 4
- 108010005774 beta-Galactosidase Proteins 0.000 claims 4
- 108010089932 heparan sulfate sulfatase Proteins 0.000 claims 4
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 2
- 208000028226 Krabbe disease Diseases 0.000 claims 2
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 claims 2
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims 2
- 208000036710 mucopolysaccharidosis type 3A Diseases 0.000 claims 2
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract 4
- 239000007924 injection Substances 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 3
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01046—Galactosylceramidase (3.2.1.46)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
Abstract
Настоящая группа изобретений относится к фармацевтической промышленности, а именно к композиции для интравентрикулярного введения для лечения лизосомной болезни накопления, ассоциированной со сниженным уровнем или активностью лизосомального фермента и к применению композиции. Предложена фармацевтическая композиция для интравентрикулярного введения для лечения лизосомной болезни накопления, ассоциированной со сниженным уровнем или активностью лизосомального фермента, причем указанная композиция содержит замещающий фермент для лизосомального фермента в концентрации 5 мг/мл или выше, до 50 мМ фосфата и имеет pH 5,5-7,0. А также применение композиции, содержащей замещающий фермент, для приготовления лекарственного средства для лечения лизосомной болезни накопления, ассоциированной со сниженным уровнем или активностью лизосомального фермента, причем указанный замещающий фермент присутствует в композиции в концентрации 5 мг/мл или выше, композиция содержит до 50 мМ фосфата при pH 5,5-7,0, и лекарственное средство предназначено для интравентрикулярного введения субъекту. Вышеописанная композиция эффективна для интравентрикулярного введения для лечения лизосомной болезни накопления, ассоциированной со сниженным уровнем или активностью лизосомального фермента, способствует эффективному диффундированию замещающего лизосомального фермента через поверхность мозга и проникновению в различные слои или области мозга, включая глубокие области мозга для эффективной доставки активных агентов в центральную нервную систему. 2 н. и 8 з.п. ф-лы, 192 ил., 28 табл.
Claims (10)
1. Фармацевтическая композиция для интравентрикулярного введения для лечения лизосомной болезни накопления, ассоциированной со сниженным уровнем или активностью лизосомального фермента, причем указанная композиция содержит замещающий фермент для лизосомального фермента в концентрации 5 мг/мл или выше, до 50 мМ фосфата и имеет pH 5,5-7,0.
2. Композиция по п. 1, отличающаяся тем, что указанная композиция дополнительно содержит один или более из (i) поверхностно-активного вещества или (ii) регулятора тоничности.
3. Композиция по п. 1, отличающаяся тем, что указанную композицию вводят в объеме одной дозы менее 5 мл.
4. Композиция по любому из пп. 1-3, отличающаяся тем, что лизосомная болезнь накопления выбрана из группы, состоящей из синдрома Хантера, метахроматической лейкодистрофии (МЛ), синдрома Санфилиппо типа А и лейкодистрофии глобоидных клеток (ЛГК).
5. Композиция по любому из пп. 1-4, отличающаяся тем, что замещающий фермент необязательно выбран из группы, состоящей из рекомбинантной идуронат-2-сульфатазы (I2S), арилсульфатазы А (ASA), гепаран N-сульфатазы (HNS) или β-галактозидазы (GLC).
6. Применение композиции, содержащей замещающий фермент, для приготовления лекарственного средства для лечения лизосомной болезни накопления, ассоциированной со сниженным уровнем или активностью лизосомального фермента, причем указанный замещающий фермент присутствует в композиции в концентрации 5 мг/мл или выше, композиция содержит до 50 мМ фосфата при pH 5,5-7,0, и лекарственное средство предназначено для интравентрикулярного введения субъекту.
7. Применение по п. 6, отличающееся тем, что композиция дополнительно содержит один или более из (i) поверхностно-активного вещества или (ii) регулятора тоничности.
8. Применение по п. 6, отличающееся тем, что композицию вводят в объеме одной дозы менее 5 мл.
9. Применение по любому из пп. 6-8, отличающееся тем, что лизосомная болезнь накопления выбрана из группы, состоящей из синдрома Хантера, метахроматической лейкодистрофии (МЛ), синдрома Санфилиппо типа А и лейкодистрофии глобоидных клеток (ЛГК).
10. Применение по любому из пп. 6-9, отличающееся тем, что замещающий фермент необязательно выбран из группы, состоящей из рекомбинантной идуронат-2-сульфатазы (I2S), арилсульфатазы А (ASA), гепаран N-сульфатазы (HNS) или β-галактозидазы (GLC).
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35885710P | 2010-06-25 | 2010-06-25 | |
US61/358,857 | 2010-06-25 | ||
US36078610P | 2010-07-01 | 2010-07-01 | |
US61/360,786 | 2010-07-01 | ||
US38786210P | 2010-09-29 | 2010-09-29 | |
US61/387,862 | 2010-09-29 | ||
US201161435710P | 2011-01-24 | 2011-01-24 | |
US61/435,710 | 2011-01-24 | ||
US201161442115P | 2011-02-11 | 2011-02-11 | |
US61/442,115 | 2011-02-11 | ||
US201161476210P | 2011-04-15 | 2011-04-15 | |
US61/476,210 | 2011-04-15 | ||
US201161495268P | 2011-06-09 | 2011-06-09 | |
US61/495,268 | 2011-06-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012154831A Division RU2626514C2 (ru) | 2010-06-25 | 2011-06-25 | Доставка к цнс лечебных агентов |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021134682A Division RU2021134682A (ru) | 2010-07-01 | 2021-11-26 | Доставка терапевтических агентов в цнс |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017125281A RU2017125281A (ru) | 2019-01-31 |
RU2017125281A3 RU2017125281A3 (ru) | 2020-11-09 |
RU2761342C2 true RU2761342C2 (ru) | 2021-12-07 |
Family
ID=45352777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017125281A RU2761342C2 (ru) | 2010-06-25 | 2011-06-25 | Доставка терапевтических агентов в цнс |
Country Status (24)
Country | Link |
---|---|
US (14) | US9814764B2 (ru) |
JP (21) | JP6250616B2 (ru) |
CN (4) | CN105233277B (ru) |
AR (6) | AR081679A1 (ru) |
BR (1) | BR112012033214B1 (ru) |
CA (1) | CA3171308A1 (ru) |
CL (7) | CL2012003654A1 (ru) |
DK (3) | DK3626257T3 (ru) |
ES (3) | ES2896060T3 (ru) |
HK (2) | HK1214149A1 (ru) |
HR (3) | HRP20211520T1 (ru) |
HU (6) | HUE056884T2 (ru) |
LT (3) | LT3626258T (ru) |
MX (1) | MX354776B (ru) |
NZ (2) | NZ702800A (ru) |
PE (8) | PE20130579A1 (ru) |
PL (1) | PL2588130T3 (ru) |
PT (6) | PT3103469T (ru) |
RS (3) | RS61683B1 (ru) |
RU (1) | RU2761342C2 (ru) |
SI (3) | SI3626258T1 (ru) |
SM (1) | SMT201600385B (ru) |
TW (8) | TWI602573B (ru) |
UA (2) | UA125060C2 (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
EP2182980A4 (en) | 2007-07-27 | 2012-04-18 | Armagen Technologies Inc | METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS |
EP3533467B1 (en) | 2009-10-09 | 2023-07-26 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
RU2012154576A (ru) | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
ME03647B (me) | 2010-06-25 | 2020-07-20 | Shire Human Genetic Therapies | Postupci i kompozicije za isporuku arilsulfataze a u cns |
PL2588130T3 (pl) | 2010-06-25 | 2017-09-29 | Shire Human Genetic Therapies, Inc. | Dostarczanie środków terapeutycznych do OUN |
IL291554B2 (en) | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
EA201792099A1 (ru) | 2011-12-23 | 2018-05-31 | Шир Хьюман Дженетик Терапис, Инк. | Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы |
EP2793922B1 (en) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
KR20160010526A (ko) * | 2013-05-15 | 2016-01-27 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
KR20180090387A (ko) * | 2015-12-30 | 2018-08-10 | 주식회사 녹십자 | 헌터증후군을 치료하기 위한 방법 및 조성물 |
BR112018017322A2 (pt) * | 2016-02-24 | 2019-01-02 | Biomarin Pharm Inc | proteínas de fusão de enzima lisossômica terapêuticas direcionadas, formulações associadas e usos das mesmas |
KR20190008237A (ko) | 2016-04-15 | 2019-01-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
JP7449223B2 (ja) | 2017-09-22 | 2024-03-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ii型を治療するための遺伝子療法 |
KR20200126994A (ko) * | 2018-02-28 | 2020-11-09 | 세이가가쿠 고교 가부시키가이샤 | 포장체 및 그 제조 방법 |
CN108534695A (zh) * | 2018-05-04 | 2018-09-14 | 无锡恩特卫自动化检测设备有限公司 | 一种基于机器视觉系统的瓶塞漏酒检测方法及装置 |
KR20210024082A (ko) | 2018-06-25 | 2021-03-04 | 제이씨알 파마 가부시키가이샤 | 단백질 함유 수성 액제 |
JP7253771B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
JP7253770B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
MX2023004335A (es) | 2020-10-14 | 2023-05-04 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas. |
CN113283465B (zh) * | 2021-04-02 | 2022-04-29 | 电子科技大学 | 一种弥散张量成像数据分析方法及装置 |
CN115116623A (zh) * | 2022-06-28 | 2022-09-27 | 深圳市儿童医院 | 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089462A2 (en) * | 2004-03-18 | 2005-09-29 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
WO2006054309A2 (en) * | 2004-11-22 | 2006-05-26 | Mediwound Ltd. | Debriding composition from bromelain |
US20060177433A1 (en) * | 2002-04-25 | 2006-08-10 | Treco Douglas A | Treatment of alpha-galactosidase a deficiency |
US20090017005A1 (en) * | 2003-08-29 | 2009-01-15 | Biomarion Pharmaceutical Inc. | Delivery of Therapeutic Compounds to the Brain and Other Tissues |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133001A (en) * | 1959-11-26 | 1964-05-12 | Muset Pedro Puig | Stabilization of enzymes |
US4743265A (en) | 1986-04-23 | 1988-05-10 | Dij Catheter Corp | Articulated catheter placement device |
US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
ES2164098T3 (es) * | 1993-02-02 | 2002-02-16 | Xoma Technology Ltd | Composiciones farmaceuticas que contienen una proteina bactericida aumentadora de la permeabilidad y un tensioactivo. |
US5863782A (en) * | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
AU735216B2 (en) | 1997-08-22 | 2001-07-05 | Seikagaku Corporation | Therapeutic agent for herniated intervertebral disc |
AU3113700A (en) | 1998-12-07 | 2000-06-26 | Genzyme Corporation | Treatment of pompe's disease |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US6368315B1 (en) | 1999-06-23 | 2002-04-09 | Durect Corporation | Composite drug delivery catheter |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
US20020099025A1 (en) * | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
US6866844B2 (en) * | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
JP2005506340A (ja) | 2001-10-16 | 2005-03-03 | シムバイオンティクス インコーポレイテッド | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
WO2003068159A2 (en) | 2002-02-11 | 2003-08-21 | Wake Forest University | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
AU2003237314B2 (en) | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
SI2332567T1 (sl) | 2003-01-31 | 2015-08-31 | The Mount Sinai School Of Medicine Of New York University | Kombinirana terapija za zdravljenje motenj pomanjkanja proteina |
CA2515603C (en) | 2003-02-10 | 2016-06-07 | To-Bbb Holding B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
CA2554883C (en) | 2004-01-30 | 2013-10-01 | Zymenex A/S | Production and purification of recombinant arylsulfatase a |
US20060029656A1 (en) | 2004-02-03 | 2006-02-09 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
WO2005077093A2 (en) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
US20050244400A1 (en) | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
BRPI0510271A (pt) * | 2004-06-15 | 2007-10-30 | Baxter Int | aplicações ex-vivo agentes terapêuticos microparticulados |
KR20070046919A (ko) * | 2004-08-11 | 2007-05-03 | 시바 스페셜티 케미칼스 홀딩 인크. | 효소계 시간 온도 인디케이터 |
WO2006121199A1 (ja) * | 2005-05-11 | 2006-11-16 | Oxygenix Co., Ltd. | 脂質小胞体組成物 |
JP2009509913A (ja) | 2005-06-08 | 2009-03-12 | アミカス セラピューティックス インコーポレイテッド | リソソーム酵素をコードする遺伝子の変異に関連するcns障害の治療 |
AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
EP1988823B1 (en) | 2006-02-09 | 2018-08-15 | Genzyme Corporation | Slow intraventricular delivery |
CN101410408A (zh) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
MX2008012748A (es) | 2006-04-04 | 2009-01-07 | Shire Pharmaceuticals Ireland | Un proceso para la concentracion de un polipeptido. |
GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
WO2008070769A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Intrathecal catheter |
WO2008109677A2 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
WO2009017005A1 (ja) | 2007-07-27 | 2009-02-05 | Sharp Kabushiki Kaisha | 移動局装置、基地局装置、通信システム及びプログラム |
JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス, インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
EP2223934B1 (en) * | 2007-11-14 | 2012-10-03 | Institute Of Microbiology, Chinese Academy Of Sciences | Polypeptides for inhibiting influenza virus infection |
US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
WO2009131698A2 (en) | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
JP5627571B2 (ja) | 2008-05-07 | 2014-11-19 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム標的化ペプチドおよびその使用 |
US8436489B2 (en) | 2009-06-29 | 2013-05-07 | Lightsail Energy, Inc. | Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange |
WO2011163652A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
PL2588130T3 (pl) | 2010-06-25 | 2017-09-29 | Shire Human Genetic Therapies, Inc. | Dostarczanie środków terapeutycznych do OUN |
ME03647B (me) | 2010-06-25 | 2020-07-20 | Shire Human Genetic Therapies | Postupci i kompozicije za isporuku arilsulfataze a u cns |
IL291554B2 (en) | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
RU2012154576A (ru) | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
WO2011163651A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE |
JP6045492B2 (ja) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | イズロン酸−2−スルファターゼのcns送達のための方法および組成物 |
JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
EP2793922B1 (en) * | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
-
2011
- 2011-06-25 PL PL11799035T patent/PL2588130T3/pl unknown
- 2011-06-25 SI SI201132007T patent/SI3626258T1/sl unknown
- 2011-06-25 PT PT161791504T patent/PT3103469T/pt unknown
- 2011-06-25 HU HUE19192508A patent/HUE056884T2/hu unknown
- 2011-06-25 CA CA3171308A patent/CA3171308A1/en active Pending
- 2011-06-25 CN CN201510512218.XA patent/CN105233277B/zh active Active
- 2011-06-25 LT LTEP19192679.9T patent/LT3626258T/lt unknown
- 2011-06-25 MX MX2013000321A patent/MX354776B/es active IP Right Grant
- 2011-06-25 DK DK19192508.0T patent/DK3626257T3/da active
- 2011-06-25 CN CN201610569581.XA patent/CN106139133B/zh active Active
- 2011-06-25 HR HRP20211520TT patent/HRP20211520T1/hr unknown
- 2011-06-25 CN CN201610086722.2A patent/CN105664142A/zh active Pending
- 2011-06-25 PE PE2012002475A patent/PE20130579A1/es active IP Right Grant
- 2011-06-25 PE PE2018000183A patent/PE20180801A1/es unknown
- 2011-06-25 RS RS20210291A patent/RS61683B1/sr unknown
- 2011-06-25 PT PT117990366T patent/PT2593131T/pt unknown
- 2011-06-25 PE PE2012002498A patent/PE20130648A1/es not_active Application Discontinuation
- 2011-06-25 HU HUE11799037A patent/HUE046409T2/hu unknown
- 2011-06-25 RU RU2017125281A patent/RU2761342C2/ru active
- 2011-06-25 ES ES19192508T patent/ES2896060T3/es active Active
- 2011-06-25 HR HRP20211660TT patent/HRP20211660T1/hr unknown
- 2011-06-25 PE PE2012002476A patent/PE20130589A1/es not_active Application Discontinuation
- 2011-06-25 NZ NZ702800A patent/NZ702800A/en not_active IP Right Cessation
- 2011-06-25 PE PE2012002474A patent/PE20130578A1/es not_active Application Discontinuation
- 2011-06-25 ES ES16179150T patent/ES2858726T3/es active Active
- 2011-06-25 NZ NZ702803A patent/NZ702803A/en unknown
- 2011-06-25 PT PT117990374T patent/PT2585104T/pt unknown
- 2011-06-25 LT LTEP19192508.0T patent/LT3626257T/lt unknown
- 2011-06-25 PE PE2017001612A patent/PE20180130A1/es unknown
- 2011-06-25 HU HUE19192679A patent/HUE055963T2/hu unknown
- 2011-06-25 RS RS20211191A patent/RS62520B1/sr unknown
- 2011-06-25 PE PE2017000503A patent/PE20170938A1/es unknown
- 2011-06-25 BR BR112012033214-7A patent/BR112012033214B1/pt active IP Right Grant
- 2011-06-25 PT PT191925080T patent/PT3626257T/pt unknown
- 2011-06-25 DK DK16179150.4T patent/DK3103469T3/da active
- 2011-06-25 HU HUE11799035A patent/HUE031036T2/en unknown
- 2011-06-25 HU HUE16179150A patent/HUE052944T2/hu unknown
- 2011-06-25 PT PT117990358T patent/PT2588130T/pt unknown
- 2011-06-25 SI SI201131959T patent/SI3103469T1/sl unknown
- 2011-06-25 UA UAA201507719A patent/UA125060C2/uk unknown
- 2011-06-25 LT LTEP16179150.4T patent/LT3103469T/lt unknown
- 2011-06-25 RS RS20211359A patent/RS62620B1/sr unknown
- 2011-06-25 UA UAA201507529A patent/UA125743C2/uk unknown
- 2011-06-25 ES ES19192679T patent/ES2895655T3/es active Active
- 2011-06-25 SI SI201132014T patent/SI3626257T1/sl unknown
- 2011-06-25 CN CN201510172262.0A patent/CN104857504A/zh active Pending
- 2011-06-25 HU HUE11799036A patent/HUE046856T2/hu unknown
- 2011-06-25 PT PT191926799T patent/PT3626258T/pt unknown
- 2011-06-25 DK DK19192679.9T patent/DK3626258T3/da active
- 2011-06-25 PE PE2012002479A patent/PE20130637A1/es not_active Application Discontinuation
- 2011-06-27 TW TW100122534A patent/TWI602573B/zh active
- 2011-06-27 AR ARP110102243A patent/AR081679A1/es unknown
- 2011-06-27 TW TW106135183A patent/TWI669128B/zh active
- 2011-06-27 TW TW100122529A patent/TW201212936A/zh unknown
- 2011-06-27 AR ARP110102242A patent/AR081678A1/es not_active Application Discontinuation
- 2011-06-27 TW TW109118555A patent/TWI790444B/zh active
- 2011-06-27 AR ARP110102244A patent/AR081680A1/es unknown
- 2011-06-27 AR ARP110102246A patent/AR082025A1/es not_active Application Discontinuation
- 2011-06-27 TW TW112102995A patent/TW202337489A/zh unknown
- 2011-06-27 TW TW106108970A patent/TWI609694B/zh active
- 2011-06-27 TW TW105115109A patent/TW201701899A/zh unknown
- 2011-06-27 AR ARP110102245A patent/AR081681A1/es unknown
- 2011-06-27 AR ARP110102241A patent/AR081677A1/es not_active Application Discontinuation
- 2011-06-27 TW TW106127273A patent/TWI698252B/zh active
-
2012
- 2012-12-21 CL CL2012003654A patent/CL2012003654A1/es unknown
- 2012-12-21 CL CL2012003657A patent/CL2012003657A1/es unknown
- 2012-12-21 CL CL2012003655A patent/CL2012003655A1/es unknown
- 2012-12-21 CL CL2012003656A patent/CL2012003656A1/es unknown
-
2013
- 2013-05-10 US US13/892,076 patent/US9814764B2/en active Active
- 2013-08-23 US US13/974,457 patent/US9220677B2/en active Active
-
2015
- 2015-11-11 US US14/938,824 patent/US20160158324A1/en not_active Abandoned
- 2015-12-03 JP JP2015236539A patent/JP6250616B2/ja active Active
- 2015-12-17 JP JP2015246258A patent/JP2016040335A/ja not_active Withdrawn
- 2015-12-17 JP JP2015246244A patent/JP6285409B2/ja active Active
- 2015-12-17 JP JP2015246589A patent/JP2016094451A/ja active Pending
- 2015-12-18 JP JP2015246952A patent/JP6346162B2/ja active Active
-
2016
- 2016-02-04 US US15/016,141 patent/US10456454B2/en active Active
- 2016-02-25 HK HK16102145.2A patent/HK1214149A1/zh unknown
- 2016-03-22 US US15/077,046 patent/US20170042977A1/en not_active Abandoned
- 2016-06-13 HK HK16106769.8A patent/HK1218719A1/zh unknown
- 2016-10-27 SM SM201600385T patent/SMT201600385B/it unknown
- 2016-12-07 CL CL2016003159A patent/CL2016003159A1/es unknown
-
2017
- 2017-08-23 US US15/684,568 patent/US10646554B2/en active Active
- 2017-09-15 JP JP2017177784A patent/JP6466538B2/ja active Active
- 2017-09-26 US US15/715,748 patent/US11065307B2/en active Active
- 2017-10-03 CL CL2017002488A patent/CL2017002488A1/es unknown
- 2017-10-04 JP JP2017194348A patent/JP6522072B2/ja active Active
- 2017-10-04 JP JP2017194508A patent/JP6522073B2/ja active Active
-
2018
- 2018-07-16 US US16/036,584 patent/US11065308B2/en active Active
- 2018-10-11 JP JP2018192589A patent/JP6797876B2/ja active Active
- 2018-12-03 JP JP2018226358A patent/JP6898909B2/ja active Active
- 2018-12-04 JP JP2018227369A patent/JP6938456B2/ja active Active
-
2019
- 2019-07-18 US US16/515,568 patent/US11260112B2/en active Active
- 2019-09-17 US US16/573,557 patent/US11471516B2/en active Active
-
2020
- 2020-01-07 JP JP2020000930A patent/JP2020079244A/ja not_active Withdrawn
- 2020-02-14 JP JP2020023620A patent/JP2020079297A/ja active Pending
- 2020-02-17 JP JP2020024183A patent/JP2020079298A/ja active Pending
- 2020-02-26 CL CL2020000468A patent/CL2020000468A1/es unknown
- 2020-03-24 US US16/828,731 patent/US20200405825A1/en active Pending
-
2021
- 2021-02-23 HR HRP20210298TT patent/HRP20210298T1/hr unknown
- 2021-06-17 US US17/350,860 patent/US20220133862A1/en active Pending
- 2021-07-13 JP JP2021115560A patent/JP7448507B2/ja active Active
- 2021-07-13 JP JP2021115564A patent/JP7087175B2/ja active Active
- 2021-08-18 JP JP2021133184A patent/JP2021181489A/ja active Pending
- 2021-12-03 JP JP2021196898A patent/JP7359827B2/ja active Active
-
2022
- 2022-01-18 US US17/578,119 patent/US20230026836A1/en active Pending
- 2022-08-16 US US17/820,155 patent/US20230165942A1/en active Pending
-
2023
- 2023-02-02 JP JP2023014814A patent/JP2023052868A/ja active Pending
- 2023-02-20 JP JP2023024170A patent/JP2023062114A/ja active Pending
- 2023-05-11 JP JP2023078673A patent/JP2023099216A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060177433A1 (en) * | 2002-04-25 | 2006-08-10 | Treco Douglas A | Treatment of alpha-galactosidase a deficiency |
US20090017005A1 (en) * | 2003-08-29 | 2009-01-15 | Biomarion Pharmaceutical Inc. | Delivery of Therapeutic Compounds to the Brain and Other Tissues |
WO2005089462A2 (en) * | 2004-03-18 | 2005-09-29 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
WO2006054309A2 (en) * | 2004-11-22 | 2006-05-26 | Mediwound Ltd. | Debriding composition from bromelain |
Non-Patent Citations (2)
Title |
---|
LEE W. C. et al., Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy, The FASEB Journal, August, 2007,vol. 21 no. 10, рр. 2520-2527. Published online before print April 2, 2007, doi:10.1096/fj.06-6169com. * |
WATSON G. et al., Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice, Gene Ther. 2006 Jun;13(11):917-25. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2761342C2 (ru) | Доставка терапевтических агентов в цнс | |
KR101859486B1 (ko) | 설하용 덱스메데토미딘 조성물과 그의 사용 방법 | |
US9833618B2 (en) | Methods and compositions for treating a disease condition in a subject | |
Mountney et al. | Sialidase, chondroitinase ABC, and combination therapy after spinal cord contusion injury | |
HRP20161505T1 (hr) | Dostava terapeutskih agensa u cns | |
RU2012154574A (ru) | Способы и композиции для доставки в цнс арилсульфатазы а | |
US20180243282A1 (en) | Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems | |
JP2018184440A (ja) | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 | |
SI2613798T2 (en) | Use of lysosomal acid lipase to treat lysosomal acid lipase deficiency in patients | |
ES2953560T3 (es) | Procedimiento para el tratamiento o reducción de paniculopatía fibrosclerótica edematosa | |
CN108379269A (zh) | 一种用于术后镇痛的缓释制剂及其制备方法 | |
JP2010526837A5 (ru) | ||
EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
Heikkinen et al. | Severe systemic reaction to topical imiquimod | |
CN102215835A (zh) | 一种医药产品及其治疗领域 | |
CN101610760B (zh) | (s)-心得乐在制备治疗恶病质的药物中的用途 | |
WO2014190063A1 (en) | Methods for the treatment of premature ejaculation | |
RU2021134682A (ru) | Доставка терапевтических агентов в цнс | |
KR101873539B1 (ko) | 저장성 지방 분해 조성물 및 그의 제조 방법 | |
CN101190184A (zh) | 一种微粉化固体外用局部麻醉剂及其制备方法 | |
KR20200092069A (ko) | 지방분해 조성물 진동분사 주입장치 | |
JP2020532555A (ja) | ダントロレンを使用して神経薬暴露を治療する方法 | |
RU2348417C1 (ru) | Способ коррекции нейроэндокринного и иммунного состояния организма (варианты) | |
CN102091326B (zh) | 治疗因肛门皮下的静脉丛发生扩大或曲张所引发的痔类疾病的经皮给药制剂及制备方法 | |
CN115804754A (zh) | 吗啡鼻喷剂及其制备方法 |